US lawmakers launch investigation into FDA approval and price of new Alzheimer’s drug

Two House committees have launched an investigation into the approval and pricing of the Alzheimer’s disease drug aducanumab, made by the company Biogen and sold under the brand name Aduhelm.

Share this:

What do you think?

Written by Headlines

Mainstream media is often "Fake News." Nevertheless, one needs to see what others are seeing and then read with discernment.

Leave a Reply

Your email address will not be published. Required fields are marked *

Canada bakes, dozens die, in record-breaking heatwave

Tensions rise in Black Sea as Russian jets conduct ‘mock attacks’ on Dutch frigate